ECO Animal Health Reports Strong H1 2025 Results and Advances R&D Milestones

Eco Animal Health ( (GB:EAH) ) has provided an update.

ECO Animal Health Group reported strong financial results for the first half of 2025, with a 19% increase in revenue to £39.4 million and a significant improvement in gross margins to 49.6%. The company attributed this growth to increased sales volumes, price improvements, and lower input costs, leading to an adjusted EBITDA of £3.0 million. Additionally, ECO received a Positive Opinion from the European Medicines Agency for its poultry vaccine, ECOVAXXIN® MS, marking a significant milestone in its R&D pipeline and setting the stage for a commercial launch in the EU in the second half of 2026.

The most recent analyst rating on (GB:EAH) stock is a Hold with a £94.00 price target. To see the full list of analyst forecasts on Eco Animal Health stock, see the GB:EAH Stock Forecast page.

Spark’s Take on GB:EAH Stock

According to Spark, TipRanks’ AI Analyst, GB:EAH is a Neutral.

Eco Animal Health’s overall stock score is primarily influenced by its stable financial position and positive technical indicators. However, the high P/E ratio suggests overvaluation, and inconsistent revenue growth poses a risk to future profitability. The absence of earnings call data and corporate events limits additional insights.

To see Spark’s full report on GB:EAH stock, click here.

More about Eco Animal Health

ECO Animal Health is a global leader in animal health, specializing in the development and marketing of veterinary pharmaceuticals, particularly antibiotics and vaccines for pigs and poultry. The company is headquartered in the UK and operates globally, holding marketing authorizations in over 70 countries.

Average Trading Volume: 71,878

Technical Sentiment Signal: Buy

Current Market Cap: £63.69M

See more insights into EAH stock on TipRanks’ Stock Analysis page.